About WHO

Recent corporate evaluations

Programmatic Evaluations

Preliminary evaluation of the WHO global coordination mechanism on the prevention and control of noncommunicable diseases (2017)

The terms of reference of the WHO global coordination mechanism on the prevention and control of noncommunicable diseases included a preliminary evaluation of the mechanism by the World Health Assembly, to take place in 2017, in order to assess its results and added value. This preliminary evaluation has been completed and will be submitted to the Seventy-first Health Assembly, through the WHO Executive Board at its 142nd session.

EB142/15 Add.1:

Review of the Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products (2017)

In 2012, the Sixty-fifth World Health Assembly adopted resolution WHA65.19, in which it decided to establish a Member State mechanism aimed at protecting public health and promoting access to affordable, safe, efficacious, and quality medical products, by promoting the prevention and control of substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) medical products and associated activities. This resolution renewed and re-established a mandate for the Secretariat and Member States in addressing SSFFC medical products from a public health perspective in a transparent and inclusive way. The Member State mechanism is supported by WHO and facilitated by the mechanism secretariat.

A review of the Member State mechanism was mandated by the above resolution and conducted by the WHO Evaluation Office. A review of the Member State mechanism was mandated by the above resolution and conducted by the WHO Evaluation Office.

A70/23 Add.1:

Comprehensive Evaluation of the Implementation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (2016)

The global strategy on public health, innovation and intellectual property aims to promote new thinking on innovation and access to medicines and, based on the recommendations of the report of the Commission on Intellectual Property Rights, Innovation and Public Health, provide a medium-term framework for securing an enhanced and sustainable basis for needs-driven essential health research and development relevant to diseases that disproportionately affect developing countries, proposing clear objectives and priorities for research and development, and estimating funding needs in this area.

The overall purpose of this comprehensive evaluation was to assess the status of implementation of the eight elements of the global strategy and plan of action, its 25 sub-elements and 108 specific actions. It looked at such implementation by all stakeholders listed in the action plan at different levels (global, regional and national), including national governments, the WHO Secretariat and other relevant stakeholders.

Covering the period 2008–2015, the evaluation documented achievements, gaps and remaining challenges and the evaluators have identified areas for future work and proposed recommendations which the overall programme review, planned for 2017, may wish to consider.